Lucid Diagnostics LUCD
Relative Strength Index (RSI)
- The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.
- The RSI is calculated using the following formula:
RSI = 100 - (100 / (1 + RS))
Where RS is the ratio of the average gains to the average losses over a specified period.
- The default time period used is 14 days.
- RSI values range between 0 and 100.
RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)
RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)
RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.
Jump To Section
$
About
Lucid Diagnostics (LUCD) Business Model and Operations Summary
Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company. The company focuses on patients with gastroesophageal reflux disease, which is also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma. Its lead products include EsoGuard, a laboratory developed esophageal DNA test; and EsoCheck, an esophageal cell collection device. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. is a subsidiary of PAVmed Inc.
Key Insights
Lucid Diagnostics (LUCD) Stock Information & Key Business Metrics
Market Cap
$147.56 MillionAverage Daily Volume
915,239 Shares52-Week Range
$0.95-$1.80Free Cash Flow
-$46.44 MillionTotal Outstanding Shares
203.07 Million SharesFree Float
150.48 Million Shares (77.1% Outstanding)CEO
Lishan AklogTotal Employees
82Current Dividend
No dividendIPO Date
October 14, 2021Headquarters
360 Madison Avenue, New York, NY, 10017